Vir Biotechnology (VIR) Asset Writedowns and Impairment (2020 - 2024)

Vir Biotechnology has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $11.0 million in Q4 2024.

• Quarterly Asset Writedowns and Impairment rose 300.07% year-over-year to $11.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $11.0 million (down 20.0% YoY) and the FY2024 annual result came in at $14.6 million, up 50.65% from the prior year.
• Asset Writedowns and Impairment climbed to $11.0 million in Q4 2024 per VIR's latest filing, from $2.8 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $11.0 million in Q4 2024 and troughed at $800000.0 in Q3 2020.
• A 3-year average of $4.9 million and a median of $2.8 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 300.07% in 2024, down 300.07% in 2024.
• Over 3 years, Asset Writedowns and Impairment stood at $800000.0 in 2020, then soared by 244.88% to $2.8 million in 2023, then jumped by 300.07% to $11.0 million in 2024.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $11.0 million, $2.8 million, and $800000.0 for Q4 2024, Q4 2023, and Q3 2020 respectively.